Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Eur J Pharmacol ; 397(1): 75-84, 2000 May 26.
Artigo em Inglês | MEDLINE | ID: mdl-10844101

RESUMO

The effect of gamma-hydroxybutyrate on the histological and behavioral consequences of transient brain ischemia was studied in the four vessel occlusion rat model. In saline-treated animals, 30 min ischemia caused a massive loss of neurons in the hippocampal CA1 subfield (normal neurons: 14%, 5%, 23% and 30% on the 3rd, 10th, 15th and 65th day after ischemia, respectively). gamma-Hydroxybutyrate - 300 mg/kg intraperitoneally (i.p.) 30 min before or 10 min after arteries occlusion, followed by 100 mg/kg i.p. twice daily for the following 10 days - afforded a highly significant protection (normal neurons on the 3rd, 10th, 15th and 65th day after ischemia: 88% and 91%, 80% and 80%, 91% and 90%, 72% and 71% in rats receiving the first dose before or after arteries occlusion, respectively). The ischemia-induced sensory-motor impairment was significantly attenuated in rats receiving the first dose of gamma-hydroxybutyrate before arteries occlusion. Finally, the ischemia-induced impairment in spatial learning and memory, evaluated starting 27 days after the ischemic episode, was significantly attenuated by gamma-hydroxybutyrate, either injected first at 30 min before or 10 min after arteries occlusion. Lower doses of gamma-hydroxybutyrate had no significant effect. In conclusion, these results indicate that gamma-hydroxybutyrate provides significant protection against both histological and behavioral consequences of transient global cerebral ischemia in rats.


Assuntos
Isquemia Encefálica/fisiopatologia , Hipocampo/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Oxibato de Sódio/farmacologia , Animais , Hipocampo/patologia , Aprendizagem/efeitos dos fármacos , Masculino , Memória/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Neurônios/patologia , Desempenho Psicomotor/efeitos dos fármacos , Ratos , Ratos Wistar , Córtex Somatossensorial/efeitos dos fármacos , Córtex Somatossensorial/fisiopatologia , Comportamento Espacial/efeitos dos fármacos
2.
Alcohol Alcohol ; 33(2): 126-30, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9566474

RESUMO

The present study assessed the efficacy of the cannabinoid CB1 receptor antagonist, SR-141716, in reducing voluntary ethanol intake in selectively bred Sardinian alcohol-preferring (sP) rats. Ethanol (10%, v/v) and food were available in daily 4 h scheduled access periods; water was present 24 h/day. The acute administration of a 2.5 and a 5 mg/kg dose of SR-141716 selectively reduced ethanol intake, whereas a 10 mg/kg dose of SR-141716 reduced to a similar extent both ethanol and food intake. These results suggest that the cannabinoid CB1 receptor is involved in the mediation of the ethanol-reinforcing effects in sP rats.


Assuntos
Consumo de Bebidas Alcoólicas/tratamento farmacológico , Canabinoides/antagonistas & inibidores , Piperidinas/uso terapêutico , Pirazóis/uso terapêutico , Consumo de Bebidas Alcoólicas/genética , Consumo de Bebidas Alcoólicas/psicologia , Animais , Depressores do Sistema Nervoso Central/sangue , Ingestão de Líquidos/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Etanol/sangue , Masculino , Ratos , Ratos Endogâmicos , Ratos Wistar , Receptores de Canabinoides , Receptores de Droga/antagonistas & inibidores , Rimonabanto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA